Assessment of Serum Catestatin Level in Acne Vulgaris Patients
ConditionAcne Vulgaris
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorAswan University
About this trial
Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults.
Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.
Eligibility criteria
Qualifiers
Healthy persons of both sexes with moderate and severe acne.
Disqualifiers
Pregnant and lactating women.
Immunocompromised patients.
Severe anemia.
History of chronic liver disease.
Trial design
Treatments tested in this trial
- Isotretinoin
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov